Johnson & Johnson (JNJ) Scheduled to Post Quarterly Earnings on Tuesday
Johnson & Johnson (NYSE:JNJ) will be issuing its quarterly earnings data before the market opens on Tuesday, January 23rd. Analysts expect the company to announce earnings of $1.72 per share for the quarter.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, topping analysts’ consensus estimates of $1.80 by $0.10. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The company had revenue of $19.65 billion during the quarter, compared to analyst estimates of $19.29 billion. During the same quarter last year, the firm posted $1.68 earnings per share. The firm’s revenue was up 10.3% on a year-over-year basis. On average, analysts expect Johnson & Johnson to post $7 EPS for the current fiscal year and $8 EPS for the next fiscal year.
Shares of Johnson & Johnson (JNJ) opened at $145.76 on Tuesday. Johnson & Johnson has a 52 week low of $110.76 and a 52 week high of $146.42. The company has a market capitalization of $391,590.00, a price-to-earnings ratio of 25.31, a P/E/G ratio of 2.75 and a beta of 0.80. The company has a quick ratio of 1.02, a current ratio of 1.32 and a debt-to-equity ratio of 0.36.
A number of brokerages recently commented on JNJ. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $120.00 price target on shares of Johnson & Johnson in a research note on Wednesday, October 4th. Vetr lowered Johnson & Johnson from a “hold” rating to a “sell” rating and set a $130.49 price target for the company. in a research note on Monday, September 18th. Stifel Nicolaus raised their price target on Johnson & Johnson from $140.00 to $142.00 and gave the stock a “hold” rating in a research note on Wednesday, October 18th. Wells Fargo & Co raised Johnson & Johnson from a “market perform” rating to an “outperform” rating and raised their price target for the stock from $140.00 to $149.00 in a research note on Monday, October 9th. Finally, JPMorgan Chase & Co. lowered Johnson & Johnson from an “overweight” rating to a “neutral” rating in a research note on Tuesday, January 2nd. Four investment analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have given a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $145.94.
A number of institutional investors have recently made changes to their positions in JNJ. Harding Loevner LP purchased a new position in Johnson & Johnson during the second quarter valued at $106,000. IHT Wealth Management LLC lifted its position in Johnson & Johnson by 46.4% during the second quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock valued at $122,000 after buying an additional 3,467 shares during the period. Mountain Capital Investment Advisors Inc purchased a new position in Johnson & Johnson during the second quarter valued at $124,000. Lenox Wealth Management Inc. lifted its position in Johnson & Johnson by 1.7% during the second quarter. Lenox Wealth Management Inc. now owns 1,457 shares of the company’s stock valued at $193,000 after buying an additional 24 shares during the period. Finally, Intercontinental Wealth Advisors LLC purchased a new position in Johnson & Johnson during the second quarter valued at $200,000. 65.71% of the stock is owned by institutional investors and hedge funds.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.